- Home
- MERC vs KOD Comparison
MERC vs KOD Comparison
Compare MERC & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- KOD
- Stock Information
- Founded
- MERC 1968
- KOD 2009
- Country
- MERC Canada
- KOD United States
- Employees
- MERC N/A
- KOD N/A
- Industry
- MERC Paper
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MERC Basic Materials
- KOD Health Care
- Exchange
- MERC Nasdaq
- KOD Nasdaq
- Market Cap
- MERC 271.5M
- KOD 259.6M
- IPO Year
- MERC 1987
- KOD 2018
- Fundamental
- Price
- MERC $3.58
- KOD $3.40
- Analyst Decision
- MERC Hold
- KOD Hold
- Analyst Count
- MERC 3
- KOD 3
- Target Price
- MERC $5.33
- KOD $9.00
- AVG Volume (30 Days)
- MERC 707.8K
- KOD 440.1K
- Earning Date
- MERC 05-01-2025
- KOD 05-14-2025
- Dividend Yield
- MERC 8.37%
- KOD N/A
- EPS Growth
- MERC N/A
- KOD N/A
- EPS
- MERC N/A
- KOD N/A
- Revenue
- MERC $1,996,904,000.00
- KOD N/A
- Revenue This Year
- MERC $2.43
- KOD N/A
- Revenue Next Year
- MERC $6.12
- KOD N/A
- P/E Ratio
- MERC N/A
- KOD N/A
- Revenue Growth
- MERC N/A
- KOD N/A
- 52 Week Low
- MERC $3.20
- KOD $1.92
- 52 Week High
- MERC $9.78
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- MERC 34.30
- KOD 45.30
- Support Level
- MERC $3.47
- KOD $3.46
- Resistance Level
- MERC $4.22
- KOD $3.81
- Average True Range (ATR)
- MERC 0.17
- KOD 0.42
- MACD
- MERC 0.03
- KOD -0.07
- Stochastic Oscillator
- MERC 14.67
- KOD 34.50
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.